IN THE SPECIFICATION:

On page 18, add the following new paragraph between lines 25 and 26:

Ophthalmic dosage forms in accordance with this invention contain the following active ingredients: ascorbic acid, at a preferred concentration of from about 1.3 μg/mL to about 30 μg/mL; 2-amino-2-deoxy-D-glucose, at a preferred concentration of from about 0.01 μg/mL to about 0.2 μg/mL; zinc sulfate, at a preferred concentration of from about 0.06 μg/mL to about 8.5 μg/mL; and L-lysine hydrochloride, at a preferred concentration of from about 1.6 μg/mL to about 23 μg/mL. Ophthalmic eyedrop dosage forms of this invention preferably also contain copper sulfate in a concentration ranging from about 0.4 μg/mL to about 15 μg/mL. In further preferred ophthalmic eyedrop dosage forms of this invention, heparin sodium is present in a concentration ranging from about 0.6 units/mL to about 8 units/mL. In still further preferred ophthalmic eyedrop dosage forms of this invention, N-acetyl-L-cysteine is present in a concentration ranging from about 0.02 mg/mL to about 0.5 mg/mL. In still further preferred ophthalmic eyedrop dosage forms of this invention, L-2-oxathiazolidine-4-carboxylate is present in a concentration ranging from about 0.02 mg/mL to about 0.5 mg/mL. In ophthalmic ointment or gel dosage forms of this invention, copper sulfate is preferably present at a concentration of from about 0.4 μg/mL to about 15 μg/mL. In further preferred ophthalmic ointment or gel dosage forms of this invention, quercetin is preferably present at a concentration of from about 0.12 μg/mL to about 2.75 μg/mL. In further preferred ophthalmic ointment or gel dosage forms of this invention, heparin sodium is preferably present at a concentration of from about 0.6 units/mL to about 8 units/mL. In still further preferred ophthalmic ointment or gel dosage forms of this invention, N-acetyl-L-cysteine is preferably present at a concentration of from about 0.2 units/mL to about 0.5 units/mL.